New drug cocktail aims to shrink lymphoma without chemo

NCT ID NCT04404088

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests a combination of three drugs—acalabrutinib, lenalidomide, and rituximab—in 60 people with untreated follicular lymphoma that has spread. The goal is to see if this chemo-free mix can make the cancer disappear completely. Participants take the drugs by mouth or infusion, and researchers track how many achieve a complete remission.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Acalabrutinib, lenalidomide, and rituximab
What this could lead to
If successful, this combination could offer a more effective first-line treatment for follicular lymphoma, potentially leading to higher remission rates without chemotherapy.
What could go wrong
This is a small, early-phase (Phase II) study with only 60 participants. The combination may cause side effects like infection, fatigue, or blood clots, and may not prove better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANN ARBOR STAGE III GRADE 1 FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.